WS Investor
22 Dec 2025, 09:21
BioNTech Completes CureVac Acquisition After Exchange Offer
BioNTech SE has completed its exchange offer to acquire CureVac N.V., with about 86.75 percent of CureVac shares tendered. The transaction was finalized with the issuance of BioNTech ADSs to CureVac shareholders, marking the formal close of the acquisition.
Source: BioNTech press release
BioNTech SE has completed its exchange offer to acquire CureVac N.V., with about 86.75 percent of CureVac shares tendered. The transaction was finalized with the issuance of BioNTech ADSs to CureVac shareholders, marking the formal close of the acquisition.
Source: BioNTech press release
